Patient characteristics of measurable lesion type in talimogene laherparepvec study
| Any Measurable Lesion | Evaluablea Lesion | Evaluable for overall lesion- type burdenb | |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Any | 50 (100) | 47 (100) | 37 (100) |
| At least 1 baseline uninjected lesion | 48 (96.0) | 41 (87.2) | 35 (94.6) |
| Baseline uninjected, non-visceral only | 26 (52.0) | 23 (48.9) | 23 (62.2) |
| At least 1 visceral lesion at baseline | 22 (44.0) | 15 (31.9) | 12 (32.4) |
Denominators are the numbers of patients
aEvaluable indicates at least 2 assessments with valid measurements per investigator
bEvaluable indicates at least 2 visits with non-missing overall lesion-type burden for each respective patient subgroup, or overall tumor burden for “Any”
All patients received at least one dose of talimogene laherparepvec